How Do Novel PFAS Sorbents Fit into Current Engineering Paradigm?
ACS ES&T Engineering · 11.04.2025 · 5 (4) · 830-838
DOI: 10.1021/acsestengg.5c00036 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS ES&T Engineering, online erschienen am 11.03.2025. Verfasst von Jonathan Burkhardt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Office of Research and Development, Center for Environmental Solutions & Emergency Response, U.S. Environmental Protection Agency, Cincinnati, Ohio 4…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural EPA, North Carolina General Assembly.
Abstract (Originalsprache)
As the emergence of novel sorbents brings new possibilities for treatment of per- and polyfluoroalkyl substances (PFAS), drinking water and wastewater utilities face critical decisions in selecting effective, future-ready technologies. With regulatory pressures to address PFAS contamination mounting, however, many utilities may not be in a position to fully evaluate the potential of these novel sorbents and are instead preparing to adopt established technologies that are currently available, such as granular activated carbon (GAC) and ion exchange (IX) resins. Given the expected long life spans of any chosen system, it is important to consider all options, including future treatment innovations. This perspective provides insights into their potential advantages and challenges by exploring the current state of novel sorbents within the broader context of existing technologies. Novel sorbents bring promising benefits, including enhanced selectivity, rapid kinetics, and flexibility for different PFAS chemistries, particularly in challenging matrices such as wastewater. Despite their advantages, significant work remains to refine these materials for large-scale application, including addressing scalability, cost-effectiveness, fouling resistance, and regulatory certification hurdles. By examining key factors for both utilities and novel sorbent developers, this perspective aims to guide informed decisions that balance immediate regulatory compliance with long-term adaptability.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Office of Research and Development, Center for Environmental Solutions & Emergency Response, U.S. Environmental Protection Agency, Cincinnati, Ohio 45220, United States.
- Office of Groundwater and Drinking Water, U.S. Environmental Protection Agency, Washington, D.C. 20004, United States.
- One Water Engineering, Raleigh, North Carolina 27605, United States.
- Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
- Environmental Finance Center and Department of City and Regional Planning, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
- Department of Chemical and Biomolecular Engineering, Rice University, Houston, Texas 77005, United States.
ORCID-Profile: Orlando Coronell, Ahmed Rachid El-Khattabi, Mohamed Ateia
Förderung
- Intramural EPA
- North Carolina General Assembly
Zitieren
APA
Burkhardt, J., Speth, T. F., Gorzelnik, S., Gorzalski, A. S., Coronell, O., El-Khattabi, A. R., & Ateia, M. (2025). How Do Novel PFAS Sorbents Fit into Current Engineering Paradigm?. ACS ES&T Engineering, 5(4), 830-838. https://doi.org/10.1021/acsestengg.5c00036
Vancouver
Burkhardt J, Speth TF, Gorzelnik S, Gorzalski AS, Coronell O, El-Khattabi AR, et al. How Do Novel PFAS Sorbents Fit into Current Engineering Paradigm?. ACS ES&T Engineering. 2025;5(4):830-838. doi:10.1021/acsestengg.5c00036
BibTeX
@article{Burkhardt2025,
author = {Burkhardt, Jonathan and Speth, Thomas F and Gorzelnik, Stanley and Gorzalski, Alexander S and Coronell, Orlando and El-Khattabi, Ahmed Rachid and Ateia, Mohamed},
title = {How Do Novel PFAS Sorbents Fit into Current Engineering Paradigm?},
journal = {ACS ES&T Engineering},
year = {2025},
volume = {5},
number = {4},
pages = {830--838},
doi = {10.1021/acsestengg.5c00036}
}
EUVIMED